Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given an average recommendation of “Moderate Buy” by the eight research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $26.3333.

Several analysts have recently weighed in on ANRO shares. HC Wainwright boosted their target price on shares of Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Robert W. Baird upped their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. BTIG Research began coverage on Alto Neuroscience in a research note on Monday, November 17th. They issued a “buy” rating and a $27.00 target price for the company. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Chardan Capital increased their price target on Alto Neuroscience from $15.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, January 5th.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $17.00 on Monday. The company has a market capitalization of $528.13 million, a PE ratio of -7.42 and a beta of 2.78. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $20.91. The firm has a fifty day simple moving average of $16.78 and a 200 day simple moving average of $10.62.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.14. On average, sell-side analysts forecast that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of ANRO. Invesco Ltd. bought a new position in shares of Alto Neuroscience in the first quarter valued at $67,000. AQR Capital Management LLC bought a new position in Alto Neuroscience in the 1st quarter valued at about $52,000. Vanguard Personalized Indexing Management LLC acquired a new position in Alto Neuroscience during the 2nd quarter valued at about $33,000. Ground Swell Capital LLC acquired a new position in Alto Neuroscience during the 2nd quarter valued at about $27,000. Finally, Peapod Lane Capital LLC bought a new stake in Alto Neuroscience during the 2nd quarter worth approximately $613,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.